EXAMINE study shows no extra CV events with Nesina in T2D
Data from the global EXAMINE CV safety outcomes trial indicated that Nesina (alogliptin), from Takeda, did not increase CV ischemic events in Patients with Type 2 Diabetes, including all-cause mortality (death from any cause), nonfatal myocardial infarction, nonfatal stroke, and urgent revascularization due to unstable angina. Additionally, for the post hoc composite endpoint of cardiovascular death and hospitalization for heart failure, there was no difference in event rates between the alogliptin and placebo groups (7.4% vs. 7.5%).
Data was presented at the 49th Annual Meeting of the European Association for the Study of Diabetes. Results of the global alogliptin EXAMINE trial were recently published in the New England Journal of Medicine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins